PRODUCT MONOGRAPH

Prpms-CANDESARTAN

Candesartan cilexetil tablets

 $4~\text{mg},\,8~\text{mg},\,16~\text{mg}$ and 32~mg

Angiotensin II AT₁ Receptor Blocker

PHARMASCIENCE INC.

6111 Av. Royalmount, Suite 100 Montréal, Québec H4P 2T4 Date of Revision: July 19, 2016

Submission Control No: 195306

Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION	3
SUMMARY PRODUCT INFORMATION	
INDICATIONS AND CLINICAL USE	
CONTRAINDICATIONS	4
WARNINGS AND PRECAUTIONS	4
ADVERSE REACTIONS	8
DRUG INTERACTIONS	14
DOSAGE AND ADMINISTRATION	16
OVERDOSAGE	19
ACTION AND CLINICAL PHARMACOLOGY	19
STORAGE AND STABILITY	22
DOSAGE FORMS, COMPOSITION AND PACKAGING	22
PARTII: SCIENTIFIC INFORMATION	23
PHARMACEUTICAL INFORMATION	23
CLINICAL TRIALS	24
DETAILED PHARMACOLOGY	29
TOXICOLOGY	29
REFERENCES	33
PART III: CONSUMER INFORMATION	35

^{Pr}pms-CANDESARTAN Candesartan cilexetil tablets

PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	All Non-Medicinal Ingredients
Oral	Tablets: 4 mg, 8 mg, 16 mg and 32 mg	Croscarmellose sodium, hydroxypropyl cellulose, lactose, magnesium stearate, maize starch, red iron oxide (for 8 mg, 16 mg and 32 mg), triethyl citrate.

INDICATIONS AND CLINICAL USE

pms-CANDESARTAN (candesartan cilexetil) is indicated for:

- Hypertension
 - The treatment of mild to moderate essential hypertension.
 - pms-CANDESARTAN may be used alone or concomitantly with thiazide diuretics.
 - The safety and efficacy of concurrent use with calcium channel blockers have not been established.
- Heart Failure
 - The treatment of NYHA Class II and III heart failure with ejection fraction $\leq 40\%$ in addition to standard therapy, with or without an ACE inhibitor.

Geriatrics (> 65 years of age): No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Pediatrics (6 to 17 years of age):

• Hypertension

pms-CANDESARTAN is indicated for the treatment of essential hypertension in children and adolescents 6 to 17 years of age (see CLINICAL TRIALS).

• Heart Failure

The safety and efficacy of candesartan cilexetil in the treatment of heart failure have not been established in children and adolescents <18 years.

CONTRAINDICATIONS

pms-CANDESARTAN (candesartan cilexetil) is contraindicated in:

- Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see DOSAGE FORMS, COMPOSITION AND PACKAGING section of the product monograph.
- Children aged <1 year.
- Pregnant women (see WARNINGS AND PRECAUTIONS, <u>Special Populations</u>, Pregnant Women).
- Nursing women (see WARNINGS AND PRECAUTIONS, <u>Special Populations</u>, Nursing Women).
- Combination with aliskiren-containing drugs in patients with diabetes mellitus (type 1 or type 2) or moderate to severe renal impairment (GFR < 60 mL/min/1.73m²) (see WARNINGS and PRECAUTIONS, Dual Blockade of the Renin-Angiotensin System (RAS) and Renal, and DRUG INTERACTIONS, Dual Blockade of the Renin-Angiotension-System (RAS) with ARBs, ACEIs or aliskiren-containing drugs).
- Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

When used in pregnancy, angiotensin receptor (AT₁) blockers (ARBs) can cause injury or even death of the developing fetus. When pregnancy is detected, pms-CANDESARTAN should be discontinued as soon as possible (see WARNINGS AND PRECAUTIONS, Special Populations, Pregnant Women).

<u>Cardiovascular</u>

Dual blockade of the Renin-Angiotensin System (RAS)

There is evidence that co-administration of angiotensin receptor antagonists (ARBs), such as candesartan cilexetil, or of angiotensin converting enzyme inhibitors (ACEIs) with aliskiren

increases the risk of hypotension, syncope, stroke, hyperkalemia and deterioration of renal function, including renal failure, in patients with diabetes mellitus (type 1 or type 2) and/or moderate to severe renal impairment (GFR < $60 \text{ mL/min}/1.73\text{m}^2$). Therefore, the use of pms-CANDESARTAN in combination with aliskiren-containing drugs is contraindicated in these patients (see CONTRAINDICATIONS).

Further, co-administration of ARBs, including candesartan cilexetil, with other agents blocking the RAS, such as ACEIs or aliskiren-containing drugs, is generally not recommended in other patients, since such treatment has been associated with an increased incidence of severe hypotension, decreased renal function (including acute renal failure), and hyperkalemia.

Avoid the concomitant use of ACE inhibitors and ARBs in patients with diabetic nephropathy.

If dual blockade therapy is considered necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.

Hypotension

Occasionally, symptomatic hypotension has occurred after administration of candesartan cilexetil. It is more likely to occur in patients who are volume-depleted by diuretic therapy, dietary salt restriction, dialysis, diarrhea or vomiting, or undergoing surgery with anaesthesia. In these patients, because of the potential fall in blood pressure (BP), therapy should be started under close medical supervision. Similar considerations apply to patients with ischemic heart or cerebrovascular disease, in whom an excessive fall in blood pressure could result in myocardial infarction or cerebrovascular accident.

<u>Heart Failure</u>: Patients with heart failure given candesartan cilexetil commonly have some reduction in BP. Caution should be observed when initiating therapy.

Triple combination of pms-CANDESARTAN with an ACE-inhibitor and a mineralocorticoid receptor antagonist used in heart failure is also not recommended. Use of these combinations should be under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.

Valvular Stenosis

There is concern on theoretical grounds that patients with aortic stenosis might be at particular risk of decreased coronary perfusion when treated with vasodilators because they do not develop as much afterload reduction.

Endocrine and Metabolism

Hyperkalemia

<u>Heart Failure:</u> In heart failure patients treated with candesartan cilexetil, hyperkalemia may occur. During treatment with pms-CANDESARTAN in patients with heart failure, periodic monitoring of serum potassium is recommended, especially when taken concomitantly with ACE inhibitors and potassium-sparing diuretics such as spironolactone.

<u>General</u>

Driving and Operating Machinery

The effect of candesartan cilexetil on the ability to drive and use machines has not been studied, but based on its pharmacodynamic properties candesartan cilexetil is unlikely to affect this ability. When driving vehicles or operating machines, it should be taken into account that dizziness or weariness may occur during treatment.

<u>Renal</u>

Renal Impairment

As a consequence of inhibiting the renin-angiotensin-aldosterone system (RAAS), changes in renal function have been seen in susceptible individuals. In patients whose renal function may depend on the activity of the RAAS, such as patients with bilateral renal artery stenosis, unilateral renal artery stenosis to a solitary kidney, or severe congestive heart failure, treatment with agents that inhibit this system has been associated with oliguria, progressive azotemia, and rarely, acute renal failure and/or death. In susceptible patients, concomitant diuretic use may further increase risk.

The use of ARBs, including candesartan cilexetil, or ACEIs with aliskiren-containing drugs is contraindicated in patients with moderate to severe renal impairment (GFR <60 mL/min/1.73m²) (see CONTRAINDICATIONS and DRUG INTERACTIONS, Dual Blockade of the Renin-Angiotensin-System (RAS) with ARBs, ACEIs, or aliskiren-containing drugs).

Use of pms-CANDESARTAN should include appropriate assessment of renal function.

<u>Heart Failure</u>: In heart failure patients, increases in serum creatinine may occur. Dosage reduction, and/or discontinuation of the diuretic, and/or pms-CANDESARTAN, and/or volume repletion may be required. Monitoring of serum creatinine is recommended during dose escalation and periodically thereafter.

Renal Transplantation

There is limited experience regarding the administration of candesartan cilexetil in adult patients with renal transplant.

Special Populations

Pregnant Women:

pms-CANDESARTAN is contraindicated during pregnancy (see CONTRAINDICATIONS). Drugs that act directly on the RAAS can cause fetal and neonatal morbidity and death when administered to pregnant women. When pregnancy is detected, pms-CANDESARTAN should be discontinued as soon as possible.

Epidemiological evidence regarding the risk of teratogenicity following exposure to ACEIs during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Given the current evidence available on the risk with ARBs, similar

risks may exist for this class of drugs. Patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ARBs should be stopped immediately, and, if appropriate, alternative therapy should be started.

The use of ARBs during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia).

<u>Animal data</u>: Oral doses \geq 10 mg candesartan cilexetil/kg/day administered to pregnant rats during late gestation and continued through lactation were associated with reduced survival and an increased incidence of hydronephrosis in the offspring. Candesartan cilexetil given to pregnant rabbits at an oral dose of 3 mg/kg/day caused maternal toxicity (decreased body weight and death) but, in surviving dams, had no adverse effects on fetal survival, fetal weight, or external, visceral, or skeletal development. No maternal toxicity or adverse effects on fetal development were observed when oral doses \leq 1000 mg candesartan cilexetil/kg/day were administered to pregnant mice.

Nursing Women: It is not known whether candesartan is excreted in human milk, but significant levels have been found in the milk of lactating rats. Because many drugs are excreted in human milk, and because of their potential for adversely affecting the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatrics (6 to 17 years of age):

In utero exposure: Infants with a history of *in utero* exposure to ARBs should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as a means of reversing hypotension and/or substituting for impaired renal function; however, limited experience with those procedures has not been associated with significant clinical benefit. Candesartan cilexetil is not removed from plasma by dialysis.

<u>Animal data-Heart development:</u> In preclinical studies in normotensive neonatal and juvenile rats, candesartan caused a reduction in relative and absolute heart weights. As in adult animals, these effects were considered to result from the pharmacological action of candesartan. At the lowest dose of 10 mg/kg, exposure to candesartan was 7-54x those found in children aged 6 to <17 years who received 16 mg of candesartan cilexetil. Since a NOAEL (no observed adverse effect level) could not be established in these studies, the safety margin for the effects on heart weight could not be determined. The clinical relevance of this finding is unknown.

<u>Black pediatric patients:</u> The antihypertensive effect of candesartan is less pronounced in Black patients compared with non-Black patients.

<u>Volume-depleted patients:</u> For children with possible intravascular volume depletion (e.g. patients treated with diuretics, particularly those with impaired renal function), pms-

CANDESARTAN treatment should be initiated under close medical supervision and a lower starting dose should be considered (see DOSAGE AND ADMINISTRATION, Pediatrics).

<u>Renal impairment:</u> Candesartan cilexetil has not been studied in children aged 6 to 17 years with renal impairment (see DOSAGE AND ADMINISTRATION, Pediatrics).

There is no experience regarding the administration of candesartan cilexetil in children aged 6 to <17 years with a renal transplant.

<u>Hepatic impairment:</u> There are no data on the effects of candesartan cilexetil in pediatric patients with hepatic impairment.

<u>Type 1 diabetes:</u> There is no experience regarding the administration of candesartan cilexetil in children aged 6 to <17 years with type 1 diabetes.

Geriatrics (> 65 years of age): No overall differences in safety or effectiveness were observed between subjects >65 years of age and younger subjects. In addition, other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

ADVERSE REACTIONS

Adverse Drug Reaction Overview

Hypertension

Adults:

Potentially serious adverse reactions reported rarely with candesartan cilexetil in controlled clinical trials were syncope and hypotension.

Pediatrics (6 to 17 years of age):

The adverse reaction profile of candesartan cilexetil as a treatment for hypertension in pediatric patients appeared similar to that seen in adults. However, the frequency of all adverse events (AEs) seemed higher.

Sinus arrhythmia, which was not reported in adults, was observed in 2.9% and 2.0% of pediatric patients taking candesartan cilexetil for 4 weeks and 1 year, respectively.

Heart Failure

Severe adverse reactions most commonly seen in adult heart failure patients taking candesartan cilexetil in controlled clinical trials were hypotension, hyperkalemia and renal impairment.

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

Hypertension

Adults

Table 1

Candesartan cilexetil was evaluated for safety in >8700 patients treated for hypertension, including 677 treated for \geq 6 months and 626 for \geq 1 year. Of these, 8694 were treated with candesartan cilexetil monotherapy in controlled clinical trials.

In placebo-controlled clinical trials, discontinuation due to AEs occurred in 2.9% and 2.7% of patients treated with candesartan cilexetil monotherapy and placebo, respectively.

Adverse events that occurred in > 1% of nationts regardless of drug relationship

In the double blind, placebo-controlled trials, the overall incidence of AEs showed no association with dose, age or gender. In these trials, the following AEs reported with candesartan cilexetil occurred in $\geq 1\%$ of patients, regardless of drug relationship:

	Candesartan cilexetil n = 1388	Placebo $n = 573$	
	(%)	(%)	
Body as a Whole			
Back pain	3.2	0.9	
Fatigue	1.5	1.6	
Abdominal pain	1.5	1.3	
Peripheral edema	1.0	0.7	
Digestive			
Nausea	1.9	1.3	
Diarrhea	1.5	1.9	
Vomiting	1.0	1.2	
Nervous/Psychiatric			
Headache	10.4	10.3	
Dizziness	2.5	2.3	
Respiratory			
Upper respiratory infection	5.1	3.8	
Coughing	1.6	1.1	
Influenza-like symptoms	1.5	0.8	
Pharyngitis	1.5	0.4	
Bronchitis	1.1 1.0	2.2	
Rhinitis	1.0	0.4	

Clinical trials in which doses \leq 32 mg were administered did not result in a significant increase in any of the AEs listed above.

Pediatrics (6 to 17 years of age)

Candesartan cilexetil was evaluated for safety in 240 hypertensive pediatric patients aged 6 to 17 years during a 4-week placebo-controlled clinical trial and in 235 pediatric patients in the 1-year open-label extension study. A total of 213 pediatric patients from the placebo-controlled trial enrolled in the open-label study. There were 178 patients who were treated for \geq 1 year.

The adverse reaction profile of candesartan cilexetil in pediatric patients appeared similar to that seen in adults. However, the frequency of all AEs seemed higher.

In the placebo-controlled clinical trial, the most common AEs (\geq 3% of patients) were cough, dizziness, headache, pharyngolaryngeal pain and upper respiratory tract infection. Dizziness was the most common drug-related AE.

In the open-label extension study, 3 out of 240 pediatric patients aged 6 to 17 years experienced worsening renal disease. The association between candesartan and the exacerbation of the underlying condition could not be excluded.

Sinus arrhythmia, which was not reported in adults, was observed in 2.9% and 2.0% of pediatric patients taking candesartan cilexetil for 4 weeks and 1 year, respectively.

Heart Failure

The AE profile of candesartan cilexetil in adult heart failure patients was consistent with the pharmacology of the drug and the health status of the patients. In the CHARM-Alternative and CHARM-Added studies comparing candesartan cilexetil in total daily doses \leq 32 mg once daily to placebo, 23.2% of candesartan cilexetil and 18.4% of placebo patients discontinued the treatment due to AEs.

In these trials, the following AEs reported with candesartan cilexetil occurred in $\ge 1\%$ of patients and with higher frequency than placebo, regardless of drug relationship.

	Candesartan cilexetil n = 2289	Placebo n = 2287
	(%)	(%)
Body as a Whole	<u> </u>	
Fatigue	1.4	0.9
Cardiovascular Disorders		
Hypotension	20.9	11.0
Syncope	3.3	3.2
Coronary artery disorder	4.2	3.5
Cardiac arrest	1.3	1.1
Blood Disorders		
Anemia	2.8	2.3
Gastro-Intestinal System Disorders		
Diarrhea	2.4	1.1
Gastroenteritis	1.1	0.7
Liver and Biliary System Disorders		
Cholelithiasis	1.1	0.9
Metabolic and Nutritional Disorders		
Hyperkalemia	7.6	2.6
Dehydration	2.5	1.3
Nonprotein nitrogen increased	1.3	0.3
Uremia	1.1	0.5
Gout	1.0	0.9
Musculo-Skeletal System Disorders		
Arthrosis	1.2	1.0
Nervous System Disorders		
Dizziness	3.4	2.1
Headache	1.0	0.7
Urinary System Disorders		
Renal function abnormal	14.3	7.2
Renal failure acute	3.0	1.8

Table 2Adverse events reported in CHARM-Alternative and CHARM-Added and occurring with
frequency of $\geq 1\%$ regardless of drug relationship

Less Common Clinical Trial Adverse Drug Reactions (<1%)

Hypertension

The following AEs were reported at an incidence of < 1% in controlled clinical trials (in > 1 patient, with higher frequency than placebo):

Body as a Whole: allergy, asthenia, pain, syncope.

<u>Cardiovascular</u>: angina pectoris, circulatory failure, flushing, hypotension, myocardial infarction, peripheral ischemia, thrombophlebitis.

<u>Central and Peripheral Nervous System:</u> hypertonia, hypoesthesia, paresthesia, vertigo. <u>Gastrointestinal:</u> constipation, dry mouth, dyspepsia, toothache. <u>Hearing:</u> tinnitus. <u>Metabolic and Nutritional:</u> diabetes mellitus, hyperkalemia, hyponatremia. <u>Musculoskeletal:</u> arthritis, arthropathy, myalgia, myopathy, skeletal pain, tendon disorder. <u>Blood:</u> anemia, epistaxis. <u>Psychiatric:</u> depression, impotence, neurosis. <u>Reproductive:</u> menopausal symptoms. <u>Resistance Mechanism:</u> otitis. <u>Respiratory:</u> laryngitis. <u>Skin:</u> eczema, pruritus, rash, skin disorder, sweating, (rarely) urticaria. <u>Urinary:</u> abnormal urine, cystitis. <u>Vision:</u> conjunctivitis.

AEs reported at a rate >1% but at about the same or greater incidence in patients receiving placebo, in studies using daily doses >16 mg: albuminuria, arthralgia, chest pain and sinusitis.

Other AEs reported at an incidence of $\geq 0.5\%$ from >3200 patients treated worldwide include anxiety, dyspnea, fever, gastroenteritis, hematuria, hyperglycemia, hypertriglyceridemia, hyperuricemia, increased creatinine phosphokinase, palpitation, somnolence and tachycardia.

Heart Failure

The following listed AEs occurred in <1% of patients treated with candesartan cilexetil but in \geq 2 patients and with more frequent occurrence in the candesartan cilexetil group than in the placebo group (CHARM-Alternative and CHARM-Added).

<u>Skin and Appendages Disorders:</u> angioedema, pruritus, rash. <u>Liver and Biliary System Disorders:</u> hepatic function abnormal. <u>White Cell and Resistance Disorders:</u> granulocytopenia, leukopenia.

Abnormal Hematologic and Clinical Chemistry Findings

Laboratory Test Findings

Hypertension

In controlled clinical trials, clinically important changes in standard laboratory parameters were rarely associated with administration of candesartan cilexetil.

Liver Function Tests: In controlled clinical trials, elevations of AST and ALT (> 3x the upper limit of normal) occurred in 0.3% and 0.5%, respectively, of patients treated with candesartan cilexetil monotherapy compared to 0.2% and 0.4%, respectively, of patients receiving placebo.

Serum Potassium: A small increase (mean increase of 0.1 mEq/L) was observed in hypertensive patients treated with candesartan cilexetil alone but was rarely of clinical importance.

Creatinine, Blood Urea Nitrogen, and Sodium: Infrequent minor increases in blood urea nitrogen (BUN) and serum creatinine as well as decreases in sodium were observed.

Hemoglobin and Hematocrit: Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.2 g/dL and 0.5 volume %, respectively) were observed in patients treated with candesartan cilexetil alone but were rarely of clinical importance. Anemia, leukopenia and thrombocytopenia were associated with withdrawal of 1 patient each from clinical trials.

Hyperuricemia: Hyperuricemia was rarely found (0.6% of patients treated with candesartan cilexetil and 0.5% of patients treated with placebo).

Heart Failure

Increases in serum creatinine, potassium and urea, and decreases in hemoglobin and hematocrit were observed.

Post-Market Adverse Drug Reactions

In post-marketing experience, the following have been reported in patients treated with candesartan cilexetil:

Blood and lymphatic disorders: thrombocytopenia

Cardiac disorders: atrial fibrillation, bradycardia, cardiac failure, palpitations

Digestive: abnormal hepatic function and hepatitis

Gastrointestinal disorders: pancreatitis

General disorders and administration site conditions: chest pain, malaise, sudden death

Hematologic: agranulocytosis, leukopenia and neutropenia

Immunologic: angioedema, involving swelling of the face, lips and/or tongue, hypersensitivity

Infections and infestations: pneumonia

Investigations: blood creatinine increased, fall

Metabolic and Nutritional Disorders: hyperkalemia and hyponatremia

Musculoskeletal System: muscle pain, muscle weakness, myositis and rhabdomyolysis

Nervous system disorders: cerebrovascular accident, loss of consciousness, presyncope

Psychiatric disorders: confusional state

Respiratory System Disorders: cough, pulmonary edema

Skin and Appendages Disorders: pruritus, rash and urticarial

Urogenital System: renal impairment, including renal failure in elderly susceptible patients (see WARNINGS AND PRECAUTIONS, <u>Renal</u>, Renal Impairment for definition of susceptible patients)

DRUG INTERACTIONS

Overview

In vitro studies indicate that cytochrome P450 isoenzyme CYP 2C9 is involved in the biotransformation of candesartan to its inactive metabolite. Based on in *vitro* data, no interaction would be expected to occur *in vivo* with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4.

Interaction studies have only been performed in adults.

Drug-Drug Interactions

The drugs listed in Table 3 are based on either drug interaction case reports or studies or potential interactions due to the expected magnitude and seriousness of the interaction (i.e. those identified as contraindicated).

Drug/Drug Class	Reference	Effect	Clinical Comment
Agents Increasing Serum Potassium	Τ	Candesartan cilexetil decreases the production of aldosterone.	Potassium-sparing diuretics or potassium supplements or other drugs that may increase potassium levels (e.g., heparin, co-trimoxazole) should be given only for documented hypokalemia and with frequent monitoring of serum potassium. Potassium-containing salt substitute should also be used with caution.
Diuretics	СТ	Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of	The possibility of symptomatic hypotension with the use of candesartan cilexetil can be minimized by discontinuing the diuretic prior to initiation of treatmen and/or lowering the initial dose of

 Table 3
 Established or Potential Drug-Drug Interactions with candesartan cilexetil

Drug/Drug Class	Reference	Effect	Clinical Comment
		blood pressure after initiation of therapy with candesartan cilexetil.	candesartan cilexetil (see WARNINGS AND PRECAUTIONS, <u>Cardiovascular</u> , Hypotension and DOSAGE AND ADMINISTRATION). No drug interactions of clinical significance have been identified with thiazide diuretics in patients treated with ≤25 mg hydrochlorothiazide with 16 mg candesartan cilexetil for 8 weeks.
Digoxin	СТ	Combination treatment with candesartan cilexetil and digoxin in healthy volunteers had no effect on AUC or C_{max} values for candesartan compared to candesartan cilexetil alone.	No dosage adjustment.
Dual blockade of the Renin-Angiotensin System (RAS) with ARBs, ACEIs or aliskiren-containing drugs	СТ	Clinical trial data has shown that dual blockade of the renin-angiotensin- system (RAS) through the combined use of ACE- inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAS- acting agent.	Dual blockade of the RAS with ARBs or ACEIs and aliskiren-containing drugs is contraindicated in patients with diabetes and/or renal impairment (see CONTRAINDICATIONS). The combined use of ARBs, ACEIs or aliskiren-containing drugs is generally not recommended [see WARNINGS AND PRECAUTIONS, Dual Blockade of the Renin- Angiotensin-System (RAS)].
Enalapril	СТ	While there is no clinically relevant interaction between candesartan and enalapril, patients with renal impairment showed a higher exposure to both drugs. This is consistent with the known pharmacokinetics of these 2 compounds.	Dosage may need to be adjusted based on the response of the patient.
Lithium Salts	СТ	As with other drugs which eliminate sodium, lithium clearance may be reduced.	Serum lithium levels should be monitored carefully if lithium salts are to be administered.

Drug/Drug Class	Reference	Effect	Clinical Comment
Non-steroidal anti- inflammatory drugs (NSAIDs)	СТ	Attenuation of the antihypertensive effect may occur when simultaneously administering ARBs and NSAIDs; i.e. selective COX-2 inhibitors, acetylsalicylic acid and non-selective NSAIDs. As with ACEIs,	The combination ARBs and NSAIDs should be administered with caution, especially in older patients and in volume depleted patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and periodically thereafter.
		concomitant use of ARBs and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function.	
Warfarin	СТ	When candesartan cilexetil was administered at 16 mg once daily under steady state conditions, no pharmacodynamic effect on prothrombin time was demonstrated in subjects stabilized on warfarin	No dosage adjustment.
Other		No significant drug interactions have been reported with glyburide, nifedipine or oral contraceptives co- administered with candesartan cilexetil to healthy volunteers.	No dosage adjustment.

Legend: C= Case Study; CT= Clinical Trial; T= Theoretical

Drug-Food Interactions

pms-CANDESARTAN may be taken with or without food (see DOSAGE AND ADMINISTRATION).

DOSAGE AND ADMINISTRATION

Dosing Considerations

The dosage of pms-CANDESARTAN (candesartan cilexetil) must be individualized.

Recommended Dose and Dosage Adjustment

pms-CANDESARTAN should be taken once daily, at approximately the same time each day, with or without food.

Hypertension

Adults

Initiation of therapy requires consideration of recent antihypertensive treatment, the extent of BP elevation, salt restriction, and other pertinent clinical factors. The dosage of other antihypertensive agents used with pms-CANDESARTAN may need to be adjusted. BP response is dose related over the range of 4 - 32 mg.

The recommended initial dose of pms-CANDESARTAN is 16 mg, once daily when used as monotherapy. Total daily doses of pms-CANDESARTAN should range from 8 - 32 mg. Doses >32 mg do not appear to have a greater effect on BP reduction, and there is relatively little experience with such doses. Most of the antihypertensive effect is present within 2 weeks and the maximal BP reduction is generally obtained within 4 weeks. For patients with possible depletion of intravascular volume (e.g. patients treated with diuretics, particularly those with impaired renal function) consideration should be given to administration of a lower dose. If BP is not controlled by pms-CANDESARTAN alone, a thiazide diuretic may be added (See DRUG INTERACTIONS, <u>Drug-Drug Interactions</u>, Diuretics).

Concomitant Diuretic Therapy

In patients receiving diuretics, pms-CANDESARTAN therapy should be initiated with caution, since these patients may be volume-depleted and thus more likely to experience hypotension following initiation of additional antihypertensive therapy.

Whenever possible, all diuretics should be discontinued 2-3 days prior to the administration of pms-CANDESARTAN, to reduce the likelihood of hypotension (see WARNINGS AND PRECAUTIONS, Cardiovascular, Hypotension). If this is not possible because of the patient's condition, pms-CANDESARTAN should be administered with caution and the BP monitored closely. Thereafter, the dosage should be adjusted according to the individual response of the patient.

Hepatic Impairment

Mild to moderate hepatic impairment: No dosage adjustment is necessary.

Severe hepatic impairment and/or cholestasis: There is only limited experience. In patients with severely impaired hepatic function, a lower initial dose of 4 mg should be considered.

Renal Impairment

Mild renal impairment: No dosage adjustment is necessary.

Moderate or severe renal impairment or patients undergoing dialysis: A lower initial dose of 4 mg should be considered.

Geriatrics (> 65 years of age)

No dosage adjustment is necessary for elderly patients. As greater sensitivity of some older patients cannot be ruled out, appropriate caution is recommended (see WARNINGS AND PRECAUTIONS, Geriatrics).

Pediatrics (6 to 17 years of age)

• Patients weighing <50 kg: The recommended starting dose is 4 mg once daily.

In some patients whose BP is not adequately controlled, the dose can be increased to 8 mg once daily. The maximum dose is 8 mg once daily.

• Patients weighing \geq 50 kg: The recommended starting dose is 8 mg once daily.

In some patients whose BP is not adequately controlled, the dose can be increased to 16 mg once daily. The maximum dose is 16 mg once daily.

The dose should be adjusted according to BP response.

Most of the antihypertensive effect is attained within 4 weeks.

Doses >32 mg have not been studied in pediatric patients.

For children with possible intravascular volume depletion (e.g. patients treated with diuretics, particularly those with impaired renal function), pms-CANDESARTAN treatment should be initiated under close medical supervision and a lower starting dose than the general starting dose above should be considered (see WARNINGS AND PRECAUTIONS, Special Populations, Pediatrics).

Heart Failure

Adults

The usual recommended initial dose for treating heart failure is 4 mg once daily. The target dose is 32 mg once daily which is achieved by doubling the dose at approximately 2 week intervals, as tolerated by the patient. pms-CANDESARTAN can be administered with other heart failure treatments including ACEIs, beta-blockers, diuretics, digoxin, and/or spironolactone.

No initial dose adjustment is necessary for elderly patients or in patients with renal or hepatic impairment.

Pediatrics (6 to 17 years of age)

The safety and efficacy of candesartan cilexetil in the treatment of heart failure have not been established in children and adolescents <18 years of age.

Missed Dose

If a patient misses a dose of pms-CANDESARTAN and remembers within 12 hours, the patient should take the dose as soon as possible and then go back to the regular schedule. If it is more than 12 hours after the patient remembers, they should not take the missed dose; the next dose should be taken on time.

A double dose of pms-CANDESARTAN should never be taken to make up for a missed dose.

OVERDOSAGE

Limited data are available in regard to overdosage in humans. The most likely manifestations of overdosage would be hypotension, dizziness and tachycardia; bradycardia could occur from reflex parasympathetic (vagal) stimulation. In case reports detailing overdosage (\leq 672 mg candesartan cilexetil) in adults, patient recovery was uneventful.

If symptomatic hypotension should occur, supportive treatment should be instituted and vital signs monitored. The patient should be placed supine with the legs elevated. If this is not sufficient, plasma volume should be increased by infusion of, for example, isotonic saline solution. Sympathomimetic drugs may also be administered if the above-mentioned measures are not sufficient. Candesartan cilexetil is not removed from the plasma by hemodialysis.

For management of a suspected drug overdosage, contact your regional Poison Control Center Immediately

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

Candesartan cilexetil antagonizes angiotensin II by blocking the angiotensin type one (AT_1) receptor. Angiotensin II is the primary vasoactive hormone of RAAS with effects that include vasoconstriction, stimulation of aldosterone secretion and renal reabsorption of sodium.

Candesartan cilexetil, a prodrug, is rapidly converted to the active drug, candesartan, during absorption from the gastrointestinal tract.

Candesartan blocks the vasoconstrictor and aldosterone secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT_1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis. There is also an AT_2 receptor found in many tissues, but it plays no known role in cardiovascular homeostasis to date. Candesartan has a much greater affinity (> 10,000 fold) for the AT_1 receptor than for the AT_2 receptor. The strong bond between candesartan and the AT_1 receptor is a result of tight binding to and slow dissociation from the receptor.

Candesartan does not inhibit ACE, also known as kininase II, the enzyme that converts angiotensin I to angiotensin II and degrades bradykinin, nor does it bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.

Pharmacodynamics

Candesartan inhibits the pressor effects of angiotensin II infusion in a dose dependent manner. After 1 week of once-daily dosing of 8 mg candesartan cilexetil, the pressor effect was inhibited by approximately 90% at peak (4-8 hours after dosing) with approximately 50% inhibition persisting at 24 hours.

Plasma concentrations of angiotensin I, angiotensin II, and plasma renin activity, increased in a dose-dependent manner after single and repeated administration of candesartan cilexetil to adult healthy subjects, hypertensive and heart failure patients. A decrease in the plasma concentration of aldosterone was observed when 32 mg of candesartan cilexetil was administered to hypertensive patients.

Pharmacokinetics

Absorption: Following oral administration of candesartan cilexetil as a tablet, the absolute bioavailability of candesartan is estimated to be approximately 15%. After tablet ingestion, the peak serum concentration (C_{max}) is reached after 3-4 hours. Food does not affect the bioavailability of candesartan after candesartan cilexetil administration.

Distribution: The volume of distribution of candesartan is 0.13 L/kg. Candesartan is highly bound to plasma proteins (>99%) and does not penetrate red blood cells. The protein binding is constant at candesartan plasma concentrations well above the range achieved with recommended doses. In rats, it has been demonstrated that candesartan does cross the bloodbrain barrier. It has also been demonstrated in rats that candesartan passes across the placental barrier and is distributed in the fetus.

Metabolism: Candesartan cilexetil is rapidly and completely bioactivated to candesartan by ester hydrolysis during absorption from the gastrointestinal tract. It undergoes minor hepatic metabolism by O-deethylation to an inactive metabolite. *In vitro* studies indicate that cytochrome P450 isoenzyme CYP 2C9 is involved in the biotransformation of candesartan to its inactive metabolite. Based on in *vitro* data, no interaction would be expected to occur *in vivo*

with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4.

Excretion: Total plasma clearance of candesartan is 0.37 mL/min/kg, with a renal clearance of 0.19 mL/min/kg. Candesartan is mainly excreted unchanged in urine and feces (via bile). When candesartan cilexetil is administered orally, about 26% of the dose is excreted as candesartan in urine. Following an oral dose of ¹⁴C-labeled candesartan cilexetil, approximately 33% of radioactivity is recovered in urine and approximately 67% in feces. Following an intravenous (iv) dose of ¹⁴C-labeled candesartan, approximately 59% of radioactivity is recovered in urine and approximately 59% of radioactivity is recovered in urine and approximately 59% of candesartan of candesartan. The elimination half-life of candesartan is approximately 9 hours. After single and repeated administration, the pharmacokinetics of candesartan are linear for oral doses \leq 32 mg. Candesartan and its inactive metabolite do not accumulate in serum upon repeated once-daily dosing.

Special Populations and Conditions

Geriatrics: The plasma concentration of candesartan was higher in the elderly (\geq 65 years old) (C_{max} was approximately 50% higher, and AUC was approximately 80% higher) compared to younger subjects administered the same dose. The pharmacokinetics of candesartan were linear in the elderly, and candesartan and its inactive metabolite did not accumulate in the serum of these subjects upon repeated, once-daily administration.

Pediatrics (6 to 17 years of age): Pediatric (6 to 17 years of age) hypertensive patients that received a 16 mg dose of candesartan cilexetil had exposure similar to adults given the same dose. The pharmacokinetics (C_{max} and AUC) were not modified by age, sex or body weight. From the dose-ranging studies of candesartan cilexetil, there was a dose related increase in plasma candesartan concentrations.

Candesartan cilexetil pharmacokinetics have not been determined in children and adolescent (6 to 17 years of age) with renal insufficiency.

Gender: No gender-related differences in the pharmacokinetics of candesartan have been observed.

Hepatic Insufficiency:

<u>Mild to moderate hepatic impairment:</u> There was an increase in the AUC of candesartan of approximately 20%. There was no drug accumulation in plasma in these patients.

<u>Moderate to severe hepatic impairment:</u> C_{max} and AUC increased up to 5x in a very small group administered a single dose of 16 mg candesartan (see DOSAGE AND ADMINISTRATION, Hepatic Impairment).

Renal Insufficiency:

<u>Mild to moderate renal impairment (GFR 31-60 mL/min/1.73m²)</u>: C_{max} and AUC of candesartan increased by 40-60% and 50-90%, respectively, but $t_{1/2}$ was not altered, compared

to patients with normal renal function (GFR $>60 \text{ mL/min}/1.73\text{m}^2$) during repeated dosing. There was no drug accumulation in plasma.

<u>Severe renal impairment</u> (GFR 15-30 mL/min/1.73m²): The increases in C_{max} and AUC were 40-60% and 110%, respectively. The terminal $t_{\frac{1}{2}}$ of candesartan was approximately 2x in patients with severe renal impairment, and these changes resulted in some accumulation in plasma.

<u>Patients undergoing hemodialysis:</u> The pharmacokinetics of candesartan were similar to those in patients with severe renal impairment (see DOSAGE AND ADMINISTRATION, Renal Impairment).

STORAGE AND STABILITY

Store at 15°C and 30°C.

DOSAGE FORMS, COMPOSITION AND PACKAGING

Dosage Forms

pms-CANDESARTAN (candesartan cilexetil) is available in tablets of 4 mg, 8 mg, 16 mg and 32 mg.

Composition

Each tablet contains candesartan cilexetil 4 mg, 8 mg, 16 mg or 32 mg. Each tablet also contains the following non-medicinal ingredients: croscarmellose sodium, hydroxypropyl cellulose, lactose, magnesium stearate, maize starch, red iron oxide (for 8 mg, 16 mg and 32 mg), triethyl citrate.

Packaging

pms-CANDESARTAN tablets

- **4 mg:** round, biconvex, white to off-white tablets, with score line on one side and embossed with "C" above and "4" below the score line. Available in blister packs of 30 tablets.
- **8 mg**: round, biconvex, light pink to pink colored tablets, with score line on one side and embossed with "C" above and "8" below the score line. Available in bottles of 100 tablets and in blister packs of 30 tablets.
- 16 mg: round, biconvex, pink colored tablets, with score line on one side and embossed with "C" above and "16" below the score line. Available in bottles of 100 tablets and in blister packs of 30 tablets.
- **32 mg**: round, biconvex, pink colored tablets, with score line on one side and embossed with "C" above and "32" below the score line. Available in blister packs of 30 tablets.

PARTII: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper Name: candesartan cilexetil


Chemical Name:

(±)-1-[[(Cyclohexyloxy) carbonyl] oxy] ethyl, 2-ethoxy-1-[[2'-(1H-tetrazol-5yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7carboxylate C₃₃H₃₄N₆O₆

Molecular Formula:

Molecular Mass: 610.67 g/mol

Structural Formula:



Physicochemical Properties: Description: Candesartan cilexetil is a white to off-white powder. Solubility in benzyl alcohol: 205 g/L. Solubility in water is $< 5 \times 10^{-5}$ g/L. Melting Point: 163°C with decomposition

Partition Coefficient:	pH of	Partition Coefficient (K at 20 ° C)	
	Aqueous Layer	Ethyl Ether	1-Octanol
	1.1	> 1000	> 1000
	6.9	> 1000	> 1000
	8.9	141	> 1000

 $\mathbf{K} = \frac{\text{Concentration of Candesartan Cilexetil in the organic layer}}{\text{Concentration of Candesartan Cilexetil in the aqueous layer}}$

CLINICAL TRIALS

Comparative Bioavailability Studies

Single dose, randomized double-blinded, crossover, pivotal, comparative bioavailability study of pms-CANDESARTAN 8 mg Tablets was performed versus AstraZeneca Canada Inc.'s ATACAND[®] tablets, administered as 1 x 8 mg tablets in 30 healthy male non-smoking volunteers / fast state. Bioavailability data were measured and the results are summarized in the following table:

SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA

		Candesa	artan					
	(1 x 8 mg tablets, Fast)							
	From measured data							
		Geometric	e Mean					
		Arithmetic Me	an (CV %)					
Parameter Test [*] Reference [†] % Ratio of Geometric Means 90% Confidence I								
AUC _T	701.50	676.73	103.66	97.05-110.72				
(ng·h/mL)	715.95 (21.67)	703.13 (28.99)						
AUCI	739.12	718.84	102.82	96.65-109.39				
(ng·h/mL)	753.78 (21.17)	746.89 (29.07)						
C _{max}	78.00	74.57	104.60	96.78-113.06				
(ng/mL)	80.17 (24.21)	76.76 (24.21)						
T _{max} §	4.00	4.38						
(h)	(2.34-5.50)	(2.34-5.50)						
$T_{\frac{1}{2}}^{\epsilon}$	8.87	9.32						
(h)	(40.52)	(43.99)						

* pms-CANDESARTAN, Pharmascience Inc., Montréal, Québec, Canada * ATACAND[®], AstraZeneca Canada Inc.

[§] Expressed as the median (range) only

 \in Expressed as the arithmetic mean (CV%) only

Single dose, randomized double-blinded, crossover, pivotal, comparative bioavailability study of pms-CANDESARTAN 32 mg Tablets was performed versus AstraZeneca Canada Inc.'s ATACAND[®] tablets, administered as 1 x 32 mg tablets in 30 healthy male non-smoking volunteers / fast state. Bioavailability data were measured and the results are summarized in the following table:

SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA							
	Candesartan Cilexetil						
	(1 x 32 mg tablets, Fast)						
		From measu	red data				
		Geometric	Mean				
		Arithmetic Mea	an (CV %)				
Parameter Test* Reference [†] % Ratio of Geometric Means 90% Confidence Inter							
AUC _T	2608.74	2492.39	104.67	95.18-115.11			
(ng·h/mL)	2711.34 (26.40)	2565.19 (25.15)					
AUCI	2753.75	2675.28	102.93	93.74-113.03			
(ng·h/mL)	2859.94 (26.40)						
C _{max}	249.55	231.88	107.62	96.29-120.28			
(ng/mL)	264.65 (34.53)	244.36 (32.43)					
T _{max} §	4.00	4.67					
(h)	(2.00-5.00)	(2.00-6.00)					
$T_{\frac{1}{2}}^{\epsilon}$	9.87	11.80					
(h)	(40.34)	(45.08)					

SUMMARY TABLE OF THE COM	PARATIVE BIOAVAILABILITY DATA
--------------------------	-------------------------------

¹ pms-CANDESARTAN, Pharmascience Inc., Montréal, Québec, Canada
 [†] ATACAND[®], AstraZeneca Canada Inc.
 [§] Expressed as the median (range) only

 \in Expressed as the arithmetic mean (CV%) only

Clinical Trials

Hypertension

Adults

Candesartan cilexetil causes a dose-dependent reduction in arterial blood pressure (BP). Systemic peripheral resistance is decreased, while heart rate, stroke volume and cardiac output are not significantly affected. No first dose hypotension was observed during controlled clinical trials with candesartan cilexetil.

Most of the antihypertensive effect was seen within 2 weeks of initial dosing, and the full effect in 4 weeks. With once-daily dosing, BP effect was maintained over 24 hours with trough to peak ratios of BP effect generally >80%. Candesartan cilexetil had an additional BP lowering effect when added to hydrochlorothiazide.

The antihypertensive effect was similar in men and women and in patients <65 and \geq 65 years. Candesartan was effective in reducing BP regardless of race, although the effect was somewhat less in Blacks (usually a low-renin population) than in Caucasians.

In long-term studies of ≤ 1 year, the antihypertensive effectiveness of candesartan cilexetil was maintained and there was no rebound after abrupt withdrawal.

Candesartan cilexetil reduces urinary albumin excretion in patients with type II diabetes mellitus, hypertension and microalbuminuria. In a 12-week study of 161 mildly hypertensive patients with type II diabetes mellitus, candesartan cilexetil 8-16 mg had no effect on mean A1c.

Pediatrics (6 to 17 years of age)

The antihypertensive effects of candesartan were evaluated in hypertensive children aged 6 to <17 years in a randomized, double-blind, multicentre, 4-week dose-ranging study. A total of 240 patients were randomized to receive either placebo or low (2/4 mg), medium (8/16 mg) or high (16/32 mg) doses of candesartan cilexetil in a ratio of 1:2:2:2. For children who weighed < 50 kg, the doses of candesartan cilexetil were 2, 8 or 16 mg once daily. For children who weighed \geq 50 kg, the candesartan cilexetil doses were 4, 16 or 32 mg once daily. Of those enrolled, 47% were Black patients and 29% were female; mean age ± SD was 12.9 ± 2.6 years. In addition, the majority of patients were \geq 95th percentile for body mass index (BMI) (68.8%) and suffered from primary hypertension (90.2%).

The placebo subtracted effect at trough for sitting SBP/ sitting DBP for the different doses ranged from 4.9/3.0 to 7.5/6.2 mm Hg.

In children aged 6 to <17 years, there was a trend for a lesser effect on BP in Black patients compared to non-Black patients. This was similar to what was observed in adults with hypertension.

Comparative Effects

The antihypertensive efficacy of candesartan cilexetil and losartan potassium have been compared at their once daily maximum doses, 32 mg and 100 mg, respectively, in patients with mild to moderate essential hypertension. Candesartan cilexetil lowered systolic and diastolic blood pressure by 2 to 3 mm Hg on average more than losartan potassium when measured at the time of either peak or trough effect. Both agents were well tolerated.

Heart Failure

In heart failure patients, candesartan cilexetil administration resulted in a dose-related increase in plasma renin activity and angiotensin II concentration, and a decrease in aldosterone levels.

The effects of candesartan cilexetil on mortality and hospitalization due to Congestive Heart Failure (CHF) were evaluated in 2 studies, CHARM-Alternative and CHARM-Added. These were multinational, placebo-controlled, double-blind studies in patients with New York Heart Association (NYHA) functional class II to class IV CHF. Only 3% of the patient population within each of these studies had Class IV CHF as a baseline characteristic. CHARM-Alternative (n=2,028) included patients with a LVEF \leq 40% not treated with ACE inhibitors because of intolerance. CHARM-Added (n=2,548) was carried out in patients with LVEF \leq 40% tolerant of ACE inhibitors and treated with ACE inhibitors. In these studies patients were randomized to receive either placebo or candesartan cilexetil in addition to standard therapy. Candesartan cilexetil was titrated from 4 mg or 8 mg once daily to 32 mg once daily (mean 23 mg) or the highest tolerated dose. Patients were followed for \leq 4 years, with a median of 40 months. Standard therapy included diuretics, β -blockers, ACE inhibitors, digoxin and spironolactone.

The primary composite endpoint of cardiovascular (CV) mortality or first CHF hospitalisation was significantly reduced with candesartan cilexetil in comparison with placebo in CHARM Alternative (hazard ratio (HR) 0.77, 95% CI 0.67-0.89, p<0.001) and in CHARM-Added (HR 0.85, 95% CI 0.75-0.96, p=0.011). This corresponded to a relative risk reduction of 23% and 15%, respectively.

Endpoint (time to first event)	Candesartan cilexetil (n=1013)	Placebo (n=1015)	Hazard Ratio (95% CI)	p-value (logrank)	Relative Risk Reduction	Absolute Risk Reduction
CV death or CHF hospitalisation	334	406	0.77 (0.67-0.89)	<0.001	23%	7.0%
CV death	219	252	0.85 (0.71-1.02)	0.072	15%	3.2%
CHF hospitalisation	207	286	0.68 (0.57-0.81)	<0.001	32%	7.7%

 Table 4
 CHARM – Alternative: Primary Endpoint and its Components

NOTE: In CHARM-Alternative, 14 patients needed to be treated for the duration of the study (median 34 months) to prevent 1 patient from dying of a CV event or being hospitalized for treatment of HF.

Endpoint (time to first event)	Candesartan cilexetil (n=1276)	Placebo (n=1272)	Hazard Ratio (95% CI)	p-value (logrank)	Relative Risk Reduction	Absolute Risk Reduction
CV death or CHF hospitalisation	483	538	0.85 (0.75-0.96)	0.011	15%	4.4%
CV death	302	347	0.84 (0.72-0.98)	0.029	16%	3.6%
CHF hospitalisation	309	356	0.83 (0.71-0.96)	0.013	17%	3.8%

 Table 5
 CHARM – Added: Primary Endpoint and its Components

NOTE: In CHARM-Added, 23 patients needed to be treated for the duration of the study (median 41 months) to prevent 1 patient from dying of a CV event or being hospitalised for treatment of HF.

The secondary composite endpoint of all-cause mortality or first CHF hospitalisation was also significantly reduced with candesartan cilexetil in CHARM-Alternative (HR 0.80, 95% CI 0.70-0.92, p=0.001) and CHARM-Added (HR 0.87, 95% CI 0.78-0.98, p=0.021). This corresponded to a relative risk reduction of 20% and 13%, respectively.

Treatment with candesartan cilexetil resulted in improved NYHA functional class in CHARM-Alternative (p=0.008) and CHARM-Added (p=0.020).

DETAILED PHARMACOLOGY

Acute Toxicity

Animal Pharmacology

In isolated rabbit aorta helical strips, candesartan at 3 x 10⁻¹¹ to 10⁻⁹ M decreased the maximal contractile response induced by angiotensin II. Candesartan at a concentration of 1 nM completely inhibited the response to angiotensin II in a concentration range of $10^{-10} - 10^{-7}$ M, an angiotensin II concentration which elicited a full concentration-response curve in the absence of candesartan. The dissociation rate of [³H]-candesartan binding from bovine adrenal cortical membranes, *in vitro*, was 5x slower (t_{1/2} = 66 min) than that of [¹²⁵I]-angiotensin II binding (t_{1/2} = 12 min).

Route	Species	Sex	LD ₅₀ Values	
introportional	m 01160	female	891	
intraperitoneal	mouse	male	807	
introportional	rat	female	1,210	
intraperitoneal	rat	male	940	
introvonous	100 01160	female	1,170	
intravenous	mouse	male	1,120	
introvonous	rat	female	1,550	
intravenous	rat	male	1,350	
oral study with active metabolite	100 01160	female	> 2,000 mg/kg for all	
(candesartan) and related substances	mouse	male	substances tested	
oral	100 01160	female	> 2,000 mg/kg	
0141	mouse	male		
oral	rat	female	> 2,000 mg/kg	
oral	rat	male		
oral	dog	female	> 2,000 mg/kg	
orai	dog	male		
oral (A wook study)	monkov	female	> 60 mg/kg	
oral (4 week study)	monkey	male		

TOXICOLOGY

Acute Toxicity

Table 6

Chronic Toxicity

The toxic potential of candesartan cilexetil was evaluated in a series of repeated-dose oral toxicity studies of ≤ 26 weeks in rats and ≤ 1 year in dogs. The "no toxic effect" dosage levels were concluded to be 10 mg/kg/day in the rat and 20 mg/kg/day in the dog.

Species/Strain	Number of Animals per Group	Duration and Route of Administration	Daily Dose (mg/kg)	Results
rat/F344	4 M + 4 F	4 weeks dietary	0 600 2,000 6,000	Food consumption decr. in F at 2,000 mg and in M+F at 6,000 mg dose level. Urea N ₂ incr. in M at \geq 600 mg dosing, and in F at 6,000 mg dosing. Erythrocyte count, hematocrit value, hemoglobin concentration decr. in \geq 2,000 mg groups. Extramedullary hemapoiesis in all male spleens, hypocellularity in bone marrow of 2 F and gastric ulcer/erosion in 2 F of 6,000 mg group. Hypertrophy of juxtaglomerular cells in kidneys and atrophy of zona glomerulosa in adrenal gland in all treated groups -expected pharmacological responses. "No toxic effect": 2,000 mg/kg/day.
rat/F344	10 M + 10 F	13 weeks dietary	0 300 1,000 3,000	No deaths. Body weight gain suppression in M at \geq 1,000 mg level. Slight decr. in erythrocyte count, hematocrit value, hemoglobin concentration in F of 300 mg group, M+F at \geq 1,000 mg dose. Incr. inorganic phosphorus in all M groups, decr. Triglycerides (\geq 1,000 mg male group) and incr. cholesterol (3000 mg male group).
rat/F344/Jcl	10 M + 10 F	26 weeks oral	0 1 10 100 1,000	No treatment-related deaths, nor abnormal appearance, clinical signs, opthalmoscopy and urinalysis. Decr. in body weight gain and food consumption (M, 1000 mg dose, week 25). H ₂ O intake + urine output incr. (M, 100, 1,000 mg dose). RBC parameter values decr. (M: 10-1,000 dose; F: 100-1,000 dose). Heart wt. decr. in all except M at 1 mg dose. Ratio of kidney wt:body wt. incr. in M \geq 10 mg dose, and in F \geq 100 mg dose level. In M at 1,000 mg level, incr. in adrenal wt., decr. in thymus wt. Hypertrophy of juxtaglomerular cell and intimal proliferation of interlobular arteries on kidneys of M+F at 10- 1,000 mg. Minor incr. in erosion of stomach in M+F at 1,000 mg. "No toxic effect": 10 mg/kg/day.
rat/F344/Jcl	10 M + 10 F	2 week study of candesartan cilexetil and rel.substances, oral	300 (283.2 mg can.cil. + 16.8 mg rel. sub.)	No effects by related substances on the changes caused by candesartan cilexetil alone. No toxic effects caused by related substances.

 Table 7
 Toxicity upon repeated oral administration

Species/Strain	Number of Animals per Group	Duration and Route of Administration	Daily Dose (mg/kg)	Results
dog/Beagle	3 M + 3 F	29-31 days oral gavage	0 20 100 300	No animals died during dosing. Decr. erythrocyte parameters in 1 F in each of 100 mg and 300 mg groups. Dark red focus in stomach mucosa in 1 F at 300 mg dose level. Regeneration of tubular epithelium and dilatation of kidney tubules in 1 F at 100 mg level, 2 F at 300 mg level. Mononuclear cell infiltration in kidney in 2 F in both 100 mg and 300 mg groups. Erosion of stomach mucosa in 1 F at 300 mg. No testicular abnormalities. "No toxic effect": 20 mg/kg/day.
dog/Beagle	4 M + 4 F	26 weeks oral	0 4 20 100	Suppression of body wt. and decr. erythrocyte parameters in F at 100 mg. Hypertrophy of juxtaglomerular cells at all dosage levels. Plasma levels of candesartan cilexetil dose-dependent.
dog/Beagle	4 M + 4 F	52 weeks oral	0 4 20 100 300	No clinical signs, effects on body wt., food consumption, physiological measurements, urine output, H2O intake, hemotology, coagulation, or organ wts. Hypertrophy of juxtaglomerular cells at all dosage levels. Regeneration of renal tubule incr. in 100-300 mg dose groups. Plasma levels of candesartan cilexetil and metabolite M II dose-dependent. "No toxic effect" at 20 mg/kg/day in dog.

Reproductive and Developmental Studies

Fertility

In studies concerning male and female rat fertility, no adverse effects were found on the reproductive organs. Mating performance, fertility and necropsy findings were unaffected by candesartan cilexetil treatment of males at 0-300 mg/kg/day from 9 weeks before mating to the day before necropsy, and similar findings were observed in females treated from 2 weeks before mating to day 7 of gestation. Fetuses showed no treatment-related abnormalities in mortality, weight, sex ratio, placentae or upon external, visceral or skeletal examinations.

Effects on the development of the kidneys

Animal studies with candesartan cilexetil have demonstrated late fetal and neonatal injury in the kidney. The mechanism is believed to be pharmacologically mediated through effects on the renin-angiotensin-aldosterone system (RAAS). The RAAS plays a critical role in kidney development. RAAS blockade has been shown to lead to abnormal kidney development in very young mice. Administering drugs that act directly on the RAAS, such as pms-CANDESARTAN, can alter renal development. Therefore, pms-CANDESARTAN is contraindicated in children <1 year old (see CONTRAINDICATIONS).

Mutagenicity

In vitro studies [bacterial mutagenicity, gene mutation in mammalian (mouse) cells and cytogenic tests (hamster lung cells)] showed that candesartan cilexetil has no mutagenic activity in these systems. Study at the highest doses of the candesartan metabolites (2.5 and 5 mM in the 24-hour treatment series, and 1.25 and 2.5 mM in the 48-hour treatment series) suggested cytotoxicity-mediated clastogenicity as a mechanism for the breakage-type chromosome aberration effects observed. *In vivo* studies (micronucleus test in mouse and unscheduled DNA synthesis assay in rat) indicate that candesartan cilexetil and its metabolites are neither mutagenic nor clastogenic.

Carcinogenicity

The carcinogenic potential of candesartan cilexetil was studied in rats after administration in the diet for 24 months. Dose levels were 100, 300 and 1000 mg/kg/day (50 male and 50 female rats per group). No alteration in tumour profile was observed. A 2-year oral gavage study of candesartan cilexetil in mice was performed at daily dosages of 3, 10, 30 and 100 mg/kg/day. There was no alteration in the tumour profile.